Potassium Chloride in 0.9% Sodium Chloride Injection

Each 100 mL of 20 mEq Potassium Chloride in 0.9% Sodium Chloride Injection (20 mEq K⁺/L) contains: Sodium Chloride USP 0.9 g
Potassium Chloride USP 0.15 g; Water for Injection USP qs

pH may be adjusted with Hydrochloric Acid NF

pH: 5.6 (3.5–6.5)              Calculated Osmolarity: 350 mOsmol/L

Concentration of Electrolytes (mEq/L):
Sodium 154             Potassium 20             Chloride 174

Potassium Chloride in 0.9% Sodium Chloride Injection is sterile, nonpyrogenic, hypertonic and contains no bacteriostatic or antimicrobial agents. This product is intended for intravenous administration.

The formulas of the active ingredients are:

Not made with natural rubber latex, PVC or DEHP.

The plastic container is made from a multilayered film specifically developed for parenteral drugs. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

Addition of medication should be accomplished using complete aseptic technique. The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container.

Potassium Chloride in 0.9% Sodium Chloride Injection provides electrolytes and is a source of water for hydration. It is capable of inducing diuresis depending on the clinical condition of the patient.

Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of acid-base equilibrium of body fluid.

Potassium, the principal cation of intracellular fluid, participates in carbohydrate utilization and protein synthesis, and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.

Potassium Chloride in 0.9% Sodium Chloride Injection is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration.

Potassium Chloride in 0.9% Sodium Chloride Injection is contraindicated in clinical conditions where additives of sodium, potassium or chloride could be clinically detrimental.

The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema.

Infusion of isotonic (0.9%) sodium chloride during or immediately after surgery may result in excessive sodium retention. Use the patient's circulatory system status as a guide.

In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention. Solutions containing potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended.

(See DOSAGE AND ADMINISTRATION.)

Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.

Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume.

Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain and diarrhea. The signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities and cardiac arrest. Potassium deficits result in disruption of neuromuscular function, and intestinal ileus and dilatation.

If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect.

The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

In the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.

In the event of overdosage with potassium-containing solutions, discontinue the infusion immediately and institute corrective therapy to reduce serum potassium levels.

Treatment of hyperkalemia includes the following:

1. Dextrose Injection USP, 10% or 25% containing 10 units of crystalline insulin per 20 grams of dextrose administered intravenously, 300 to 500 mL per hour.
2. Absorption and exchange of potassium using sodium or ammonium cycle cation exchange resin, orally and as retention enema.
3. Hemodialysis and peritoneal dialysis. The use of potassium-containing foods or medications must be eliminated. However, in cases of digitalization, too rapid a lowering of plasma potassium concentration can cause digitalis toxicity.

This solution is for intravenous use.

Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration.

In the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of 0.9% sodium chloride (154 mEq each of sodium and chloride).

Usually up to 40 mEq of potassium per liter daily is sufficient to replace normal loss in adults. Infusion rates should not exceed 10 mEq per hour or 120 mEq per day. A liter of fluid containing 40 mEq of potassium should be administered over an 8-hour period.

Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.

Pediatric Dosage and Administration. There is no specific pediatric dose. The dose is dependent on weight, clinical condition and laboratory results.

See WARNINGS and PRECAUTIONS.

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Potassium Chloride in 0.9% Sodium Chloride Injection is supplied sterile and nonpyrogenic in single-dose EXCEL^® Containers packaged 12 per case. 

Rx only

Revised: December 2025

EXCEL is a registered trademark of B. Braun Medical Inc.

Caution: Do not use plastic containers in series connection.

To Open

Keep in overwrap until ready for use. Tear overwrap down at notch and remove solution container. Squeeze and inspect inner bag which maintains product sterility. Discard if leaks are found. If supplemental medication is desired, follow directions below before preparing for administration.

Note: Before use, perform the following checks:

           Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date.

           Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. 
           Any container which is suspect should not be used.

           Use only if solution is clear and container is undamaged.

Preparation for Administration

1. Remove plastic protector from sterile set port at bottom of container.
2. Attach administration set. Refer to complete directions accompanying set.

To Add Medication

Warning: Some additives may be incompatible.

To Add Medication Before Solution Administration

1. Prepare medication site.
2. Using syringe with 18–22 gauge needle, puncture medication port and inner diaphragm and inject.
3. Squeeze and tap ports while ports are upright and mix solution and medication thoroughly.

To Add Medication During Solution Administration

1. Close clamp on the set.
2. Prepare medication site.
3. Using syringe with 18–22 gauge needle of appropriate length (at least 5/8 inch), puncture resealable medication port and inner diaphragm and inject.
4. Remove container from IV pole and/or turn to an upright position.
5. Evacuate both ports by tapping and squeezing them while container is in the upright position.
6. Mix solution and medication thoroughly.
7. Return container to in use position and continue administration.

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862

Y36-003-111   LD-234-6

20 mEq

POTASSIUM CHLORIDE IN

0.9% SODIUM CHLORIDE INJECTION

REF L8650

NDC 0264-7865-00

1000 mL

EXCEL^® CONTAINER

20 mEq K⁺/L

Y94-003-519   LD-502-3

FOR INTRAVENOUS INFUSION

EACH 100 mL CONTAINS     SODIUM CHLORIDE USP 0.9 g

POTASSIUM CHLORIDE USP 0.15 g     WATER FOR

INJECTION USP QS     pH MAY BE ADJUSTED WITH HCL NF

pH 5.6 (3.5-6.5)     350 mOsmol/L (CALC)     HYPERTONIC

ELECTROLYTES (mEq/L)     NA⁺ 154     K⁺ 20     CL^– 174

STERILE     SINGLE-DOSE     DISCARD UNUSED PORTION     

DO NOT USE IN SERIES CONNECTION     USE ONLY IF

SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED

WARNINGS     ADDITIVES MAY BE INCOMPATIBLE

CONSULT PHARMACIST     USE ASEPTIC TECHNIQUES

MIX THOROUGHLY     DO NOT STORE

STORE AT 20°C TO 25°C (68°F TO 77°F) [SEE USP CONTROLLED

ROOM TEMPERATURE]     AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING     SEE PACKAGE INSERT

KEEP IN OVERWRAP UNTIL READY FOR USE     SQUEEZE AND

INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY

DISCARD IF LEAKS ARE FOUND

NOT MADE WITH NATURAL RUBBER LATEX PVC OR DEHP

 Not made with Latex Not made with PVC Not made with DEHP

Rx only

EXCEL IS A REGISTERED TRADEMARK OF B. BRAUN MEDICAL INC.

B. BRAUN MEDICAL INC.
BETHLEHEM, PA 18018-3524 USA
1-800-227-2862

Y94-003-518   LD-128-4

EXP
LOT